- U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers’ trials
- Letter is latest milestone in the journey of the biomarker, discovered in 2023, to transform drug development focused on synuclein pathology — a biological hallmark of Parkinson’s, Dementia with Lewy Bodies and related neurodegenerative conditions
- FDA notes critical role of the Parkinson’s Progression Markers Initiative in generating and validating data and studies that made this landmark step forward possible
Category Archives: AZBio News
BIO5 Institute’s Kelle Hyland honored as 2024 AZBio Bioscience Educator of the Year
An integral part of the BIO5 Institute’s KEYS Research Internship program for the past 8 years, Kelle Hyland has been recognized for her extraordinary leadership and dedication by the Arizona Bioindustry Association.Continue reading
AZBioPEERS Video: Preparing for Investor Success
This AZBioPEERS webinar is presented by Richard Kovacik, JD, MBA, Managing Director of the Healthcare Growth Group. The program is designed to equip life science startups with an overview of the most important knowledge and considerations needed to attract and engage investors.Continue reading
Applications Open for ABRC Investigator Grants
The Arizona Biomedical Research Centre (ABRC) of the Arizona Department of Health Services is soliciting grant proposals for RFGA2024-022 Arizona Investigator Grant (AZ IG) or New Investigator Awards (NIA).
This is a two-phased application process. Approximately $10,5000,000 is available for biomedical grant projects over a period of three (3) years.
C-Path Announces FDA Commissioner Robert Califf to Participate in Opening Session at Inaugural Global Impact Conference
#CGIC24 Registration Nears Capacity; Closes Saturday, Aug. 31Continue reading
Multi-year, 1143-patient genetic study identifies unique types of multiple myeloma
TGen-led group confirms high-risk subgroup among cancer patientsContinue reading
C-Path Awarded $1.5 Million Grant from Ara Parseghian Medical Research Fund at Notre Dame to Enhance Collaboration in Niemann-Pick Disease Research and Drug Development
TUCSON, Ariz., August 22, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Critical Path for Lysosomal Diseases (CPLD) Consortium has been awarded a grant from the Ara Parseghian Medical Research Fund (APMRF) at the University of Notre Dame.Continue reading
C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer
TUCSON, Ariz., August 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award to Peter Wipf, Ph.D., a distinguished researcher and professor at the University of Pittsburgh, Department of ChemistryContinue reading
Calviri Named Arizona Bioscience Company of the Year
Calviri, a Phoenix, Arizona based company with a mission to end cancer worldwide and to accomplish this mission with affordable products, has been named the Arizona Bioscience Company of the Year and will be celebrated at the 20th annual AZBio Awards on September 18, 2024 at the Phoenix Convention Center.
Calviri was formed in 2017 to end cancer. The team was convinced this could be done as they had discovered a previously unappreciated, yet fundamental, molecular characteristic of all tumors that distinguishes them from healthy host cells. Calviri also invented chip technologies that would leverage their discovery to uniquely battle cancer. After years of research and many patents, Calviri is now developing multi-cancer tests to accurately detect stage 1 disease, which can be treated with its early-stage therapeutic vaccines. Calviri’s research has also shown them the path to the seeming impossible: a preventative cancer vaccine. All rooted in the power of Calviri’s molecular discoveries and semiconductor inventions, the company is now ready to globally provide diagnostics and vaccines that will end cancer. Full stop.